Cinctive Capital Management LP Has $1.63 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Cinctive Capital Management LP increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 18.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,942 shares of the company's stock after purchasing an additional 622 shares during the period. Cinctive Capital Management LP's holdings in IDEXX Laboratories were worth $1,630,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of IDXX. Cranbrook Wealth Management LLC increased its holdings in IDEXX Laboratories by 7.0% in the 4th quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock valued at $158,000 after buying an additional 25 shares during the period. Perigon Wealth Management LLC raised its position in IDEXX Laboratories by 1.8% during the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after purchasing an additional 26 shares in the last quarter. Summit Trail Advisors LLC raised its position in IDEXX Laboratories by 3.3% during the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock valued at $335,000 after purchasing an additional 26 shares in the last quarter. IFP Advisors Inc lifted its stake in IDEXX Laboratories by 3.6% during the fourth quarter. IFP Advisors Inc now owns 903 shares of the company's stock worth $373,000 after purchasing an additional 31 shares during the last quarter. Finally, Cape Cod Five Cents Savings Bank boosted its holdings in shares of IDEXX Laboratories by 0.5% in the 3rd quarter. Cape Cod Five Cents Savings Bank now owns 6,344 shares of the company's stock valued at $3,091,000 after purchasing an additional 32 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on IDXX. Piper Sandler upped their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Friday, April 4th. Barclays increased their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Finally, Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $533.75.

Insider Activity at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Trading Up 10.0 %

Shares of IDXX stock traded up $36.06 on Wednesday, hitting $397.10. The company had a trading volume of 2,190,304 shares, compared to its average volume of 609,266. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $548.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The firm has a market cap of $32.18 billion, a P/E ratio of 37.22, a P/E/G ratio of 3.41 and a beta of 1.50. The stock's 50-day moving average is $431.26 and its two-hundred day moving average is $435.73.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.